Story type: Institute

  • Better treatments sooner – Hudson’s new RNAte Platform unveiled

    Hudson Institute of Medical Research today officially unveiled its world-first RNAte platform that could see vaccines and therapeutic treatments developed faster by being able to rapidly assess their potential inflammation side effects, right here in Victoria.…  Read more

    Natalia Sampaio In the lab of the RNAte Platform at Hudson Institute
  • Hudson Institute welcomes inflammation specialist as new Centre Head

    Hudson Institute’s world leading inflammation programs enter a new era with the appointment of Professor Seth Masters to lead the Centre for Innate Immunity and Infectious Diseases (CiiiD).…  Read more

    Professor Seth Masters, Centre Head of the Centre for Innate Immunity and Infectious Diseases
  • When stomach cancer survivor becomes expert

    Despite encountering more than her share of health challenges, 92-year-old Delva Walker has the most positive outlook you are ever likely to encounter.…  Read more

    L-R Professor Richard Ferrero, Donor and cancer survivor Delva Walker and Dr Caroline Skene
  • Hudson News: Summer 2023

    Director’s Message: Changing the odds on ovarian cancer. As medical researchers, we spend a lot of our time looking at numbers, establishing which changes or effects are significant and which are not.…  Read more

    Professor Elizabeth Hartland, Director and CEO of Hudson Institute
  • Hudson CEO appointed AAMRI President

    Hudson Institute has cemented its position among Australia’s medical research leaders, with Director and CEO, Professor Elizabeth Hartland becoming President of the peak industry body.…  Read more

    Professor Elizabeth Hartland AAMRI President and Dr Saraid Billiards (CEO, AAMRI)
  • Hudson News Winter 2023

    Director’s message: For children with cancer, change starts here. Childhood cancer is rare but devastating and new treatment options are desperately needed. In the last four decades the US Food and Drug Authority (FDA) has approved 500 drugs for adult cancers but just 12 to treat childhood cancers.…  Read more

    Professor Elizabeth Hartland
  • Professor Elizabeth Hartland appointed AAMRI President Elect

    Hudson Institute’s Director and CEO, Professor Elizabeth Hartland, has been appointed the President Elect for the Association of Australian Medical Research Institutes (AAMRI). Professor Hartland will advance from her current roles as a member of the Board and the Chair of the Victorian branch of AAMRI, to take on the national leadership as President in 2023.…  Read more

    Professor Elizabeth Hartland, Director and CEO of Hudson Institute
  • State-of-the art genomic sequencer accelerates inflammation research

    Hudson Institute of Medical Research is progressing its genomic and inflammation research with the acquisition of an Illumina NextSeq 2000, a new sequencing system that provides unprecedented genomic capacity to study inflammatory diseases and microbial diversity.…  Read more

    Dr Sam Forster and Professor Elizabeth Hartland using Illumina NextSeq2000
  • Hudson Institute welcomes US cancer researcher as centre head

    Hudson Institute has welcomed its newest head of the Centre for Cancer Research, Associate Professor Ron Firestein, who has relocated from San Francisco with his young family to take up the role.…  Read more

    Associate Professor Ron Firestein and Professor Bryan Williams at Hudson Institute